Ignite Creation Date:
2025-12-25 @ 12:33 AM
Ignite Modification Date:
2026-01-01 @ 2:30 PM
Study NCT ID:
NCT00783367
Status:
COMPLETED
Last Update Posted:
2023-03-30
First Post:
2008-10-30
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
Sponsor:
Abramson Cancer Center at Penn Medicine
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
UPCC 02408
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None